Key facts
- Benchling’s last known valuation is $6.1B (Oct 2021).
- It has raised $417.9M across 2 recorded rounds; the latest was Later Stage VC (Series E) ($200.0M) in Apr 2021.
- Notable investors include Y Combinator, Andreessen Horowitz, Sequoia Capital, Spark Capital, SV Angel — 44 tracked in total.
- Benchling has filed 1 Form D with the SEC, most recently Oct 2016 ($7.0M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 44 names
- ·Watchlist + deal alerts for Benchling
Funding rounds
2 roundsAbout Benchling
Developer of a lab collaboration platform designed to make life science research quick and collaborative. The company's platform specializes in offering a suite of natively unified applications that accelerate research and development at all levels, and where scientists can design, share, and record experiments as well as share DNA-sequence data in the cloud, enabling researchers to accelerate, measure, and forecast research and development from discovery to bioprocessing, all in one place.
- Industry
- Other Healthcare Technology Systems
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2012
- Employees
- 797
- Website
- benchling.com/
- Ownership
- Privately Held (backing)
Benchling doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Benchling shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Benchling in its N-PORT filings yet. We sweep new filings monthly.